Los Angeles-Based Pelage Launches Phase 2a Trial: A New Era in Hair Loss Treatment Rooted in Stem Cell Biology
Pelage Pharmaceuticals, based in Los Angeles, has announced the commencement of its Phase 2a clinical trial for a groundbreaking treatment targeting androgenetic alopecia, commonly known as pattern hair loss. This trial marks a significant step in the company's innovative approach to combatting a condition that affects millions globally. Notable for its advanced formulation, the treatment aims to promote hair regrowth with minimal side effects compared to existing therapies. Pelage Pharmaceuticals' distinct approach and dedication to cutting-edge research underscore its potential to revolutionize the hair loss treatment landscape.